Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
NL-OMON60948Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing VHB937 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 72 in Clinical Dementia Rating scale – Sum of Boxes. Started Mar 2026; status: completed.
02
Drugs
VHB937
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60948.